Advertisement Novalyst Discovery and AliX Agree to Merge NovAliX Launch - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More


Small Molecule Drug Discovery

More info about NovAliX

Novalyst Discovery and AliX Agree to Merge NovAliX Launch

15 September 2008. Following long-standing cooperation, Novalyst Discovery, a chemistry services company, and AliX, a structural biology company, have agreed to merge to create a
leading CRO. Together they have launched NovAliX, a multidisciplinary company providing flexible
outsourcing solutions for drug discovery and development. The combined company will represent a major provider able to deliver comprehensive services from
gene to preclinical drug candidates and especially offering alternative fragment-based drug discovery

“There was a natural synergy between the two companies whose expertise in chemistry and structural
biology brings a valuable set of skills for our drug discovery program”, claimed Stephan Jenn,
President of both companies. “In the past, opportunities for joint programs have shown us that we
were able to integrate our highly complementary expertise to conduct projects successfully.”

Since the beginning of 2008, both companies have been combining operations to facilitate the
organisational process. “Our priority is to ensure that our clients receive even greater support as we go
forward as one company.” In a competitive and demanding environment the combined company
NovAliX will be a larger, stronger and more integrated organisation offering clients access to a wider
range of capabilities all the more since the integrated platform of comprehensive biological and
chemical services is advantageously complemented by a high-value added screening technology.
Indeed NovAliX has developed a unique and innovative platform using non-covalent mass
spectrometry for compound screening and binding characterisation. This mass spectrometry
technology has emerged as an alternative and efficient technique for delivering high-content
information on compound-protein interactions. Using this sensitive technique known as Fragments Analysis by MAss Spectrometry (FAMASS™) in combination with its in-house fragment library, NovAliX
proposes fragment-based drug discovery programs, a cost-effective approach for fast lead generation.

Information about integrated drug discovery research services can be found at

Quick Contact